Correction

Inhibition of miR-200b Promotes Angiogenesis in Endothelial Cells by Activating The Notch Pathway

Tie-Ying Qiu, M.M.[1], Jin Huang, M.D.[1], Li-Ping Wang, M.M.[1], Bi-Song Zhu, M.D.[2]*

1. Clinical Nursing Teaching and Research Section of The Second Xiangya Hospital, Changsha 410011, P.R. China
2. Organ Transplant Center, Xiangya Hospital, Central South University, Changsha 410008, P.R. China

Corresponding AAddress: Organ Transplant Center, Xiangya Hospital, Central South University, Changsha 410008, P.R. China
Email: 277364307@qq.com

In this article which was published in Cell J, Vol 23, No 1, Spring 2021, on pages 51-60, the authors discovered that Figures 1B, 2D, 2F, 5B, and 5D some errors that occurred accidentally during figure organization in this article. The figures below have been corrected.

The authors would like to apologies for any inconvenience caused.

Citation: Qiu TY, Huang J, Wang LP, Zhu BS. Inhibition of miR-200b promotes angiogenesis in endothelial cells by activating the notch pathway. Cell J. 2022; 24(12): 779-781. doi: 10.22074/cellj.2022.697065.
This open-access article has been published under the terms of the Creative Commons Attribution Non-Commercial 3.0 (CC BY-NC 3.0).



Fig.1: The high-glucose treatment induced the expression of miR-200b and impaired angiogenesis. **A.** Quantification of miR-200b by realtime PCR in Human umbilical vein endothelial cell (HUVECs) grown in normal glucose (NG) or high-glucose (HG) conditions for 12, 24, and 48 hours. U6 was used as an internal control for normalization. **B.** Representative images of HUVECs under different conditions during the in vitro angiogenesis assay. **C.** Quantification of secreted Vascular Endothelial Growth Factor (VEGF) from HUVECs, as determined by enzyme-linked immunosorbent assay (ELISA) after the indicated treatment (n=3). *; P<0.05, **; P<0.01, and H; Hour.



Fig.2: miR-200b affected the angiogenesis ability of human umbilical vein endothelial cell (HUVECs). The HUVECs cells were transfected with NC mimic, miR200b mimics, NC inhibitor, miR-200b inhibitor, and miR-200b transfection efficiency were analyzed by **A.** IF imaging and **B.** Real-time PCR. **C.** Quantification of HUVEC viability after the indicated treatment, as determined by CCK-8 assays. **D.** Representative images of HUVECs after the indicated treatments during the wound healing assay. **E.** Typical images and quantification of HUVECs with different treatments during the migration assay. **F.** Representative images of HUVECs under different conditions during the *in vitro* angiogenesis assay (n=3). NG; Normal glucose, HG; high-glucose, PCR; Polymerase chain reaction, *; P<0.05, and **; P<0.01.



Fig.5: miR-200b affected angiogenesis by regulating Notch1. **A.** Quantification of human umbilical vein endothelial cell (HUVEC) viability was measured by CCK-8 assay after the indicated treatments**. B.** Representative images of HUVECs after the indicated treatments during the wound healing assay. **C.** Typical images and quantification of HUVECs with different treatments during the migration assay. **D.** Representative images of HUVECs under different conditions during *in vitro* angiogenesis assays. **E.** Representative images and quantification of Notch pathway protein expression in HUVECs (n=3). NG; Normal glucose, HG; High-glucose, *; P<0.05, and **; P<0.0**1.**